mesenchymal stem cell treatment
Recently Published Documents


TOTAL DOCUMENTS

96
(FIVE YEARS 30)

H-INDEX

19
(FIVE YEARS 4)

2021 ◽  
Author(s):  
Nesrin Ercelen ◽  
Kubra Cigdem Pekkoc-Uyanik ◽  
Nagihan Alpaydin ◽  
Gokay Rasit Gulay ◽  
Murat Simsek

Abstract ObjectiveTreatment for COVID-19 is still urgent need for the critically ill and severe cases. UC-MSC administration has a therapeutic benefit for severe COVID-19 patients even in the recovery period. In this paper, we aimed to present our clinical experience with UC-MSC treatment in severe and critical severe COVID-19 patients.MethodsIn this study we evaluated the clinical outcome of severe/critically severe 210 COVID-19 patients treated with UC-MSCs, 1-2×106 per kilogram to 210 patients from 15/10/2020 until 25/04/2021. ResultsOut of 99 critically severe intubated patients we have observed good clinical progress/discharged from ICU in 52 (52.5%) patients. Where as 86 (77.5%) of 111 severe unintubated patients discharged from ICU. Intubated 47 (47.5%) patients and unintubated 25 (22.5%) patients pass away. Significantly higher survival was observed in patients who underwent UC-MSCs before intubation (OR=1.475, 95% CI=1.193-1.824 p<0.001). It was observed that the SaO2 parameter tended to improve after UC-MSC therapy compared to all groups. But SaO2 parameter between intubated and unintubated groups was not statistically significant (p>0.05), while in discharged cases SaO2 parameter was statistically significant (p= 0.01). Besides, there was a statistically significant relation with intubation status, age (OR= 3.868, 95% CI=0.574-7.152 p=0.02) and weigh (OR=6.768, 95% CI=3.423-10.112 p<0.001) thus presented an elevated risk for COVID-19. The linear regression analysis confirmed that the high weight was associated with the risk of intubation in COVID-19 (p=0.001). ConclusionsAccording to our results and from recent studies, UC-MSC treatment is safe with high potential to be used as an added therapeutic treatment for severe COVID-19 patients. Our experience showed that UC-MSC therapy may restore oxygenation and downregulate cytokine storm in patients hospitalized with severe COVID-19. We advice wider randomised studies to discover the detailed therapeutic pathophysiology of the MSCs on COVID-19 patients.


2021 ◽  
Vol 62 (3) ◽  
pp. 288-296
Author(s):  
Dragan Primorac ◽  
Sanda Stojanović ◽  
Stipić ◽  
Marko Strbad ◽  
Lenart Girandon ◽  
...  

2021 ◽  
Vol 62 (3) ◽  

COVID-19 presentations range from cold-like symptoms to severe symptoms with the development of acute respiratory distress syndrome (ARDS). We report on a severe COVID-19 patient who was mechanically ventilated and who developed ARDS and bacterial infection. Because of rapid clinical deterioration and the exhaustion of other treatment options, the family and attending physicians requested a compassionate use of adult allogenic bone marrow-derived mesenchymal stem cells (MSC) in addition to commonly used immunosuppressive, antiviral, and supportive therapy. The clinical course is discussed thoroughly, with a special emphasis on the safety and effect of MSC therapy. Compassionate MSC treatment, given in three rounds, affected ARDS regression. The patient was discharged from the intensive care unit after 31 days and from hospital after 49 days in a good general condition. MSC treatment was not associated with any side effects and was well tolerated in a three-week period; therefore, it should be studied in larger trials and considered for compassionate use.


Cytotherapy ◽  
2021 ◽  
Vol 23 (4) ◽  
pp. 23-24
Author(s):  
EM Garcez ◽  
F Saldanha-Araujo ◽  
AE Silva-Carvalho ◽  
JL Carvalho

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Yun-Xing Fu ◽  
Jing Ji ◽  
Fang Shan ◽  
Jialing Li ◽  
Rong Hu

AbstractPremature ovarian failure (POF) is one of the common disorders found in women leading to 1% female infertility. Clinical features of POF are hypoestrogenism or estrogen deficiency, increased gonadotropin level, and, most importantly, amenorrhea. With the development of regenerative medicine, human mesenchymal stem cell (hMSC) therapy brings new prospects for POF. This study aimed to describe the types of MSCs currently available for POF therapy, their biological characteristics, and their mechanism of action. It reviewed the latest findings on POF to provide the theoretical basis for further investigation and clinical therapy.


Sign in / Sign up

Export Citation Format

Share Document